Sanderson W C, Wetzler S, Asnis G M
Department of Psychiatry, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY 10467-2490.
Am J Psychiatry. 1994 Aug;151(8):1220-2. doi: 10.1176/ajp.151.8.1220.
The primary aim of this study was to determine if pretreatment with a single dose of alprazolam reduces anxiety and panic provoked by the inhalation of 35% carbon dioxide (CO2) in patients with panic disorder. Ten panic disorder patients participated in a CO2 challenge test after pretreatment with a single dose of alprazolam (1 mg p.o.) or placebo in a randomized, double-blind, within-subjects design. Seventy percent of the subjects had a panic attack with placebo, compared to only 10% with alprazolam. Alprazolam reduced the number and severity of panic symptoms and baseline anxiety significantly more than placebo. This study demonstrates the efficacy of the acute administration of alprazolam to block panic attacks and supports the usefulness of the CO2 challenge as an analogue method to study panic disorder.
本研究的主要目的是确定单剂量阿普唑仑预处理是否能减轻惊恐障碍患者吸入35%二氧化碳（CO2）引发的焦虑和惊恐。10名惊恐障碍患者在随机、双盲、自身对照设计中，接受单剂量阿普唑仑（口服1毫克）或安慰剂预处理后，参加了CO2激发试验。安慰剂组70%的受试者出现惊恐发作，而阿普唑仑组只有10%。与安慰剂相比，阿普唑仑显著减少了惊恐症状的数量和严重程度以及基线焦虑。本研究证明了急性给予阿普唑仑对阻断惊恐发作的有效性，并支持将CO2激发试验作为研究惊恐障碍的一种类似方法的实用性。
